DP031 | PROGNOSTIC IMPACT OF HIGH-RISK MUTATIONS IN SECONDARY AML TREATED WITH CPX-351: A FOCUS ON MOLECULAR PREDICTORS OF RESPONSE AND SURVIVAL

Background: Acute Myeloid Leukemia (AML) is a heterogeneous disease driven by somatic mutations. The ELN 2022 classification designated several mutations (e.g., TP53, ASXL1, SRSF2) as adverse with conventional chemotherapy. However, their prognostic significance may differ with newer treatments lik...

Fuld beskrivelse

Bibliografiske detaljer

Principais autores:	C. Riva, P. Minetto, S. Nicoletta, R. Romei, M. Chies, G. Zecchetti, E. Maio, Y. Azzanelli, N. Colombo, S. Rosellini, A. Parodi, E. Tedone, E. Carminati, F. Puglisi, C. Nurra, G. Fugazza, P. Nozza, M. Cea, R.M. Lemoli, F. Guolo
Format:	Artigo
Sprog:	Inglês
Udgivet:	Ferrata Storti Foundation 2025-09-01
Serier:	Haematologica
Online adgang:	https://haematologica.org/article/view/12795
Tags:	Tilføj Tag Ingen Tags, Vær først til at tagge denne postø!